-- Aurobindo Pharma, Jubilant Life Sciences Rated New `Buy' at Goldman Sachs
-- B y   S h i y i n   C h e n
-- 2010-10-20T00:12:15Z
-- http://www.bloomberg.com/news/2010-10-20/aurobindo-pharma-jubilant-life-sciences-rated-new-buy-at-goldman-sachs.html
Aurobindo Pharma Ltd. and Jubilant
Life Sciences Ltd. were rated “buy” in new coverage at Goldman
Sachs Group Inc., which cited an improving revenue outlook,
greater capacity utilization and easing balance sheet concerns.  The brokerage has a share-price estimate of 1,545 rupees
for Aurobindo Pharma and a forecast of 408 rupees for Jubilant
Life Sciences, according to a report by analysts including
Balaji V. Prasad.  To contact the editor responsible for this story:
Shiyin Chen at 
 schen37@bloomberg.net  